Jalramet 50 mg/850 mg AND 50 mg/1 000 mg Tablet.
PDF Leaflet Revision Date: 06 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct treatment for Type 2 diabetes mellitus.
Dosage (summary)
Starting dose based on current regimen; max vildagliptin 100 mg/day.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Safety not established; contraindicated in breastfeeding.
Key Drug Interactions
- NSAIDs
- Diuretics
- Alcohol
Contraindications
- Hypersensitivity
- Severe renal impairment (GFR < 30 ml/min)
- Hepatic impairment
- Congestive heart failure
- Metabolic acidosis
Common side effects
- Dizziness
- Nausea
- Hypoglycaemia
Counselling Points
- Take with meals to reduce GI side effects.
- Monitor renal function regularly.
- Avoid excessive alcohol intake.
Serious warnings
- Risk of lactic acidosis
- Not a substitute for insulin
- Severe cutaneous adverse reactions
Important Disclaimer
The Jalramet 50 mg/850 mg AND 50 mg/1 000 mg Tablet. professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
